A comparative study of F-18 FBPA-PET and F-18 FDG-PET in head and neck cancer

A comparative study of F-18 FBPA-PET and F-18 FDG-PET in head and neck cancer - A comparative study of FBPA-PET and FDG-PET in head and neck cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049242

Enrollment

Registered

2022-10-17

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

PET drug administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study includes patients who have been diagnosed with head and neck cancer and will be scheduled for surgery or have received radiotherapy. In addition, patients who have undergone or will undergo FDG-PET and have given written consent to participate in this study are included.

Exclusion criteria

Exclusion criteria: 1. Minors 2. Pregnant and lactating subjects or persons who wish to become pregnant 3. Others who are judged inappropriate

Design outcomes

Primary

Measure	Time frame
The whole body distribution is evaluated using PET/CT. The FBPA uptake in head and neck cancer is quantitatively measured and compared with the FDG uptake.	—

Countries

Japan

Contacts

Public ContactTadashi Watabe

Osaka University Graduate School of Medicine Department of Nuclear Medicine and Tracer Kinetics

watabe.tadashi.med@osaka-u.ac.jp06-6879-3461

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026